Description
Corcept Therapeutics Incorporated is a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol.
The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. It has marketed Korlym (mifepristone) for the treatment of patients suffering from Cushing’s syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant.
Its cortisol activity can be modulated by a drug that competes with cortisol as it attempts to bind to the glucocorticoid receptor (GR). The Company’s ingredient, mifepristone, reduces the binding of excess cortisol to GR. Its compounds bind to GR but not the progesterone, estrogen, or androgen receptors.
